What Is Semax?

Semax is a synthetic heptapeptide derived from the N-terminal fragment of adrenocorticotropic hormone (ACTH). Originally developed in Russia during the 1980s and 1990s by the Institute of Molecular Genetics of the Russian Academy of Sciences, Semax has attracted research interest due to its reported effects on neurological function in preclinical models. Its amino acid sequence is Met-Glu-His-Phe-Pro-Gly-Pro, representing a modified fragment of ACTH(4–7) with a C-terminal proline-glycine-proline extension that is believed to contribute to its stability and observed activity in animal studies.

In the context of Canadian research, Semax is classified as a research compound. It is not approved by Health Canada for human therapeutic use, and it is sold for laboratory and in-vitro research purposes only. Researchers investigating neuropeptide pharmacology, cognitive neuroscience, and BDNF (Brain-Derived Neurotrophic Factor) signalling pathways have included Semax in their study protocols.

This overview is intended strictly as an educational resource for researchers interested in the compound’s scientific background, chemical characteristics, and research literature. It does not constitute medical advice or a therapeutic recommendation.

Chemical Profile and Structure

Semax is a heptapeptide with the molecular formula C₃₇H₅₁N₉O₁₀S and a molecular weight of approximately 813.92 g/mol. Its sequence — Met-Glu-His-Phe-Pro-Gly-Pro — is based on ACTH(4–10), truncated and modified to improve metabolic stability relative to the parent hormone fragment.

Key Chemical Characteristics

• Type: Synthetic heptapeptide
• Origin: Derived from ACTH(4–7) with C-terminal extension
• Molecular Weight: ~813.92 g/mol
• CAS Number: 80714-61-0
• Stability: Typically supplied as lyophilized (freeze-dried) powder; requires cold-chain storage
• Solubility: Generally soluble in water and aqueous buffers

The structural modifications to the ACTH parent fragment — particularly the Pro-Gly-Pro C-terminal addition — are believed by researchers to confer improved resistance to enzymatic degradation, which may account for a longer active research window compared to native ACTH fragments in certain model systems.

Research Background

Semax was developed as part of a broader Soviet and later Russian program investigating neuropeptides derived from pituitary hormones. The compound emerged from research into the behavioural and neurological effects of ACTH and its fragments, which had already been studied in Western research from the 1950s onward. The addition of the proline-glycine-proline tripeptide tail to the ACTH(4–7) core was a deliberate design decision intended to produce a more metabolically stable analogue with potentially distinct pharmacological properties.

Throughout the 1990s and 2000s, Semax accumulated a body of preclinical literature, predominantly from Russian-language academic sources. This research has been of interest to Western neuroscience investigators, though it is worth noting that many studies were conducted in specific animal models and under conditions that do not translate directly to clinical application.

Research interest in Semax has expanded internationally in recent years, with investigators exploring its effects on:

• BDNF (Brain-Derived Neurotrophic Factor) expression in animal models
• Neurotrophin signalling pathways
• Cognitive and behavioural endpoints in rodent research
• Oxidative stress parameters in cell-based assays
• Neuroprotection endpoints in in-vitro models

For broader context on neuropeptide research, see our guide to research peptides explained.

Mechanisms of Interest in Research

Research into Semax has highlighted several molecular interactions that investigators find scientifically compelling. These are mechanisms observed in preclinical and in-vitro settings and should not be interpreted as established therapeutic mechanisms in humans.

BDNF Pathway Interactions

A significant portion of Semax research has focused on its apparent ability to increase BDNF mRNA expression in rodent brain tissue. BDNF is a critical neurotrophic factor involved in neuronal survival, synaptic plasticity, and learning-related processes in animal models. Preclinical studies have documented elevated BDNF levels in brain regions including the hippocampus and cortex following Semax administration in rodents, though mechanisms remain under investigation.

Dopaminergic and Serotonergic Systems

Some animal research has examined Semax’s interactions with monoaminergic systems. Investigations have reported modulation of dopamine and serotonin turnover rates in specific brain regions of rodents, though the clinical significance of these observations is not established.

Neuroprotective Parameters

In-vitro and animal-model research has investigated Semax’s effects on oxidative stress markers and neuronal cell viability under various stress conditions. These studies represent early-stage research and do not constitute evidence of neuroprotective efficacy in humans.

Immune-Related Signalling

Some preclinical research has examined Semax’s effects on cytokine expression and immune signalling in rodent models. This line of research is considered exploratory and preliminary.

Preclinical Research Overview

The preclinical literature on Semax spans several decades and research domains. Key themes in the published literature include:

Cognitive Research in Rodents

Multiple rodent studies have investigated Semax’s effects on learning and memory-related behavioural endpoints, including maze performance, passive avoidance learning, and exploratory behaviour. These animal models serve as early indicators for researchers but do not predict human cognitive outcomes.

Cerebrovascular Research Models

Russian research groups have conducted studies examining Semax in experimental stroke models in rats. These investigations documented effects on various neuropathological markers, but this research context is highly model-specific and does not translate to therapeutic conclusions.

Neurotrophin Expression Studies

Studies measuring BDNF, NGF (Nerve Growth Factor), and related neurotrophins in rodent tissue following Semax administration have been a consistent thread in the literature. The significance of these findings for human neurological research remains an active area of scientific discussion.

For related compound research context, see our articles on Selank and peptides studied in cognitive research.

Clinical Research Context

In Russia, Semax has been licensed as a pharmaceutical product for limited clinical applications, including use in stroke rehabilitation and cognitive support, under specific regulatory frameworks. This regulatory context is specific to Russia and does not reflect Health Canada approval or approval by any Western regulatory body.

Western clinical research on Semax is limited. A small number of pilot studies and clinical investigations have been conducted, primarily in Eastern European research centres. These studies represent preliminary evidence only and have not established Semax as a proven therapeutic agent by international standards.

Researchers in Canada and other Western jurisdictions classify Semax as an unregistered research compound. Any use outside a controlled, ethics-approved research environment is outside the scope of the compound’s current regulatory standing in Canada.

For information on Canadian compliance considerations for research compounds, see our guide to research compound safety and compliance.

Storage and Handling

Proper storage and handling of Semax is critical to maintaining sample integrity for research purposes. Peptides are inherently sensitive to environmental conditions, and improper storage can result in degradation, reduced purity, and compromised research outcomes.

Recommended Storage Conditions

• Long-term storage: −20°C or below in lyophilized (freeze-dried) form
• Short-term storage: 2–8°C (refrigerated) for periods not exceeding a few weeks
• Avoid: Repeated freeze-thaw cycles, exposure to direct light, humidity, and elevated temperatures
• Container: Amber glass vials or sealed multi-use vials under inert atmosphere where possible

For a comprehensive guide to peptide handling protocols for research, see our peptide storage guide.

Purity and Testing Standards

Purity is a critical variable in peptide research. At TrueCanPeptides, we provide Certificates of Analysis (CoAs) for our research compounds, enabling researchers to verify purity, identity, and quality before use in their protocols.

Standard analytical methods used to verify Semax purity and identity include:

• HPLC (High-Performance Liquid Chromatography): The primary method for assessing peptide purity percentage
• Mass Spectrometry (MS): Used to confirm molecular identity and detect impurities
• Amino Acid Analysis: Confirms sequence composition

Research-grade Semax should achieve ≥98% purity by HPLC to be considered suitable for controlled research applications. For information on what to look for in a CoA, see our guide: what is a Certificate of Analysis?

Related Research Compounds

Researchers investigating Semax often explore related neuropeptide compounds for comparative studies. Compounds of related interest include:

• Selank: A synthetic analogue of tuftsin, also developed in Russia, with research interest in anxiolytic and nootropic parameters in animal models. See our Semax vs Selank comparison.
• DSIP (Delta Sleep-Inducing Peptide): A neuropeptide studied in sleep-regulation research contexts.
• Cognitive Research Peptides: A broader overview of peptides investigated in cognitive neuroscience research.

Frequently Asked Questions

Q: What is Semax?

Semax is a synthetic heptapeptide derived from ACTH(4–7) with a C-terminal Pro-Gly-Pro extension. Developed in Russia, it has been studied in preclinical research for effects on BDNF expression, neuroprotective parameters, and cognitive endpoints in animal models. It is not approved for human use in Canada.

Q: Is Semax approved for human use in Canada?

No. Semax is not approved by Health Canada. In Canada, it is classified as a research compound sold strictly for in-vitro and laboratory research purposes. It should not be administered to humans outside of a properly approved research protocol.

Q: What has preclinical research on Semax investigated?

Preclinical research has primarily examined effects on BDNF expression in rodent brain tissue, cognitive and behavioural endpoints in animal models, neuroprotective parameters in cell assays, and monoaminergic system interactions. These are early-stage findings and do not establish human therapeutic efficacy.

Q: How should Semax be stored for research purposes?

Lyophilized Semax should be stored at −20°C or below for long-term preservation. Short-term refrigeration at 2–8°C is acceptable. Researchers should avoid repeated freeze-thaw cycles and light exposure. See our peptide storage guide for detailed protocols.

Q: What purity level is appropriate for research-grade Semax?

Research-grade Semax should achieve ≥98% purity by HPLC. A Certificate of Analysis confirming purity, identity, and absence of major contaminants should accompany any compound used in controlled research protocols.

Related Articles

• What Is Selank? Research Overview
• Semax vs Selank: Research Comparison
• Peptides for Cognitive Research
• Research Peptides Explained
• Research Compound Safety and Compliance
• What Is a Certificate of Analysis?

See also: What is Selank?